{{medical}}
{{drugbox
| IUPAC_name = 3-ethyl-''N'',''N''-bis (3-ethyl-4-methyl-2-oxo-5''H''-pyrrol-2-yl)- 4-methyl-2-oxo-5''H''-pyrrole-1- carboxamide
| image = Glimepiride Structural Formula V.1.svg
| CAS_number = 93479-97-1
| ATC_prefix = A10
| ATC_suffix = BB12
| ATC_supplemental = 
| PubChem = 3476
| DrugBank = APRD00381
| C=24 | H=34 | N=4 | O=5 | S=1
| molecular_weight = 490.617 g/mol
| bioavailability = 
| protein_bound = >99.5%
| metabolism = 
| elimination_half-life = 
| pregnancy_category = 
| legal_status = 
| routes_of_administration = 口服
}}

<!-- Definition and medical uses -->
'''格列美脲'''（{{lang-en|Glimepiride}}），為一種用以治療[[2型糖尿病|第二型糖尿病]]的藥物<ref name=AHFS2019/><ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=693|edition=76}}</ref>，目前做為[[二甲双胍|二甲双胍]]的後線藥物<ref name=AHFS2019/>。使用本品者，建議輔以飲食和運動<ref name=AHFS2019/>。格列美脲為[[口服給藥|口服藥物]]<ref name=AHFS2019/>，服用後三小時會達到最大藥效，藥效約可持續一天<ref name=AHFS2019/>。

<!-- Side effects and mechanism -->
格列美脲常見的副作用為頭痛、噁心及頭暈<ref name=AHFS2019/>，其他嚴重的副作用為[[低血糖|低血糖]]<ref name=AHFS2019/>。[[妊娠|懷孕]]或[[母乳哺育|哺乳]]者，不建議使用本藥物<ref name=Preg2019>{{cite web |title=Glimepiride Pregnancy and Breastfeeding Warnings |url=https://www.drugs.com/pregnancy/glimepiride.html |website=Drugs.com |access-date=3 March 2019 |language=en |archive-date=2019-03-06 |archive-url=https://web.archive.org/web/20190306044715/https://www.drugs.com/pregnancy/glimepiride.html |dead-url=no }}</ref>。本品的作用機轉，主要為促進胰臟分泌胰島素<ref name=AHFS2019>{{cite web |title=Glimepiride Monograph for Professionals |url=https://www.drugs.com/monograph/glimepiride.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=3 March 2019 |language=en |archive-date=2019-03-06 |archive-url=https://web.archive.org/web/20190306043009/https://www.drugs.com/monograph/glimepiride.html |dead-url=no }}</ref>；格列美脲為第二代的[[磺酰脲类|磺酰脲类]]（Sulfonylurea）藥物<ref name="pmid15531188">{{cite journal |author=Davis SN |title=The role of glimepiride in the effective management of Type 2 diabetes |journal=J. Diabetes Complicat. |volume=18 |issue=6 |pages=367–76 |year=2004 |pmid=15531188 |doi=10.1016/j.jdiacomp.2004.07.001 }}</ref>。

<!-- History and culture -->
1979年，格列美脲獲得專利，於1995年核准為醫療用途<ref>{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=449 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA449 |language=en |access-date=2022-01-03 |archive-date=2016-12-27 |archive-url=https://web.archive.org/web/20161227201818/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA449 |dead-url=no }}</ref>。本品已有[[通用名药物|學名藥]]於市面流通<ref name=BNF76/>，2019年，格列美脲在美國處方藥物中排行第62名，共開立超過1100萬劑<ref>{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=ClinCalc |access-date=16 October 2021 |archive-date=2021-02-12 |archive-url=https://web.archive.org/web/20210212142534/https://clincalc.com/DrugStats/Top300Drugs.aspx |dead-url=no }}</ref><ref>{{cite web | title=Glimepiride - Drug Usage Statistics | website=ClinCalc | url=https://clincalc.com/DrugStats/Drugs/Glimepiride | access-date=16 October 2021 | archive-date=2020-11-29 | archive-url=https://web.archive.org/web/20201129223121/https://clincalc.com/DrugStats/Drugs/Glimepiride | dead-url=no }}</ref>。

<!--'''馬爾胰'''（Amaryl）是一種硫醯基尿素類(Sulfonylurea)<ref>[http://www.ptph.doh.gov.tw/ftp/20060618094146.pdf 硫醯基尿素類(Sulfonylurea)口服降血糖錠]{{dead link|date=2018年5月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>的糖尿病药物。主要成分為Glimepiride 。用來主治[[第二型糖尿病|第二型糖尿病]]。<ref>[[:en:Diabetes_mellitus_type_2|:en:Diabetes mellitus type 2]]</ref>-->

==藥效==
*刺激[[胰臟|胰臟]]分泌較多量的[[胰島素|胰島素]]，使血糖降低。


==参考文献==
<div class="references-small">
<references />
</div>

{{口服降糖药和胰岛素类似物}}

[[Category:糖尿病药物|Category:糖尿病药物]]
[[Category:鉀通道阻滯劑|Category:鉀通道阻滯劑]]
[[Category:賽諾菲|Category:賽諾菲]]